99mTc-HYNIC-PSMA-11 Whole-Body SPECT/CT: A Clinically Viable Alternative to 68Ga-PSMA PET/CT in patients with Prostate Cancer.
1/5 보강
ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 43.7%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도
[OBJECTIVES] The diagnostic performance of 99mTc-HYNIC-PSMA-11 whole body SPECT/CT versus 68Ga-PSMA PET/CT was evaluated in prostate cancer patients.
- 표본수 (n) 10
- p-value p < 0.01
- Sensitivity 76.6%
APA
Monika H, Komalpreet K, et al. (2026). 99mTc-HYNIC-PSMA-11 Whole-Body SPECT/CT: A Clinically Viable Alternative to 68Ga-PSMA PET/CT in patients with Prostate Cancer.. The British journal of radiology. https://doi.org/10.1093/bjr/tqag052
MLA
Monika H, et al.. "99mTc-HYNIC-PSMA-11 Whole-Body SPECT/CT: A Clinically Viable Alternative to 68Ga-PSMA PET/CT in patients with Prostate Cancer.." The British journal of radiology, 2026.
PMID
41818667 ↗
Abstract 한글 요약
[OBJECTIVES] The diagnostic performance of 99mTc-HYNIC-PSMA-11 whole body SPECT/CT versus 68Ga-PSMA PET/CT was evaluated in prostate cancer patients.
[METHODS] As a part of the diagnostic workup, all the prostate cancer (PCa) patients (n = 10; mean age 66.4 ± 9.6 years) underwent whole-body 68Ga-PSMA-11 PET/CT followed by serial whole body (anterior and posterior) 99mTc-HYNIC-PSMA-11 imaging The serial whole body imaging was performed at multiple time points of 10 min, 2 h, 4 h, 6 h, 24 h and the whole body SPECT/CT was acquired at 3 h. The whole-body SPECT/CT data was analyzed for lesions detection and to calculate the standardized uptake values (SUVmax) for 99mTc-HYNIC-PSMA-11 avid lesions using the Q- Metrix software. These values were compared with the corresponding SUVmax values obtained from 68Ga-PSMA-11 PET/CT. The serial whole body imaging data were used for estimating the radiation absorbed doses (mSv/MBq) to various organs using the MIRD schema and the OLINDA/EXM software.
[RESULTS] 68Ga-PSMA-11 PET/CT identified a total of 64 metastatic lesions, while 99mTc- HYNIC-PSMA-11 SPECT/CT detected 49/64 metastatic lesions, presenting a sensitivity of 76.6%. Notably, the mean SUVmax values for 68Ga-PSMA-11 PET/CT and 99mTc-HYNIC- PSMA-11 were comparable and a highly significant positive correlation (r > 0.93; p < 0.01) The average absorbed doses to the salivary glands, lungs, kidneys, urinary bladder, and liver were found to be comparable with 99mTc-MDP bone scanning.
[CONCLUSION] The diagnostic performance of whole-body 99mTc-HYNIC PSMA-11 SPECT/CT is fairly comparable to 68Ga-PSMA PET/CT and offers a favorable dosimetry indicating its potential for PCa evaluation.
[ADVANCES IN KNOWLEDGE] 99mTc-PSMA-11 SPECT/CT may be an alternative and cost-effective tool for evaluation of initial PSMA disease burden as well as for response evaluation to PSMA targeted therapies.
[METHODS] As a part of the diagnostic workup, all the prostate cancer (PCa) patients (n = 10; mean age 66.4 ± 9.6 years) underwent whole-body 68Ga-PSMA-11 PET/CT followed by serial whole body (anterior and posterior) 99mTc-HYNIC-PSMA-11 imaging The serial whole body imaging was performed at multiple time points of 10 min, 2 h, 4 h, 6 h, 24 h and the whole body SPECT/CT was acquired at 3 h. The whole-body SPECT/CT data was analyzed for lesions detection and to calculate the standardized uptake values (SUVmax) for 99mTc-HYNIC-PSMA-11 avid lesions using the Q- Metrix software. These values were compared with the corresponding SUVmax values obtained from 68Ga-PSMA-11 PET/CT. The serial whole body imaging data were used for estimating the radiation absorbed doses (mSv/MBq) to various organs using the MIRD schema and the OLINDA/EXM software.
[RESULTS] 68Ga-PSMA-11 PET/CT identified a total of 64 metastatic lesions, while 99mTc- HYNIC-PSMA-11 SPECT/CT detected 49/64 metastatic lesions, presenting a sensitivity of 76.6%. Notably, the mean SUVmax values for 68Ga-PSMA-11 PET/CT and 99mTc-HYNIC- PSMA-11 were comparable and a highly significant positive correlation (r > 0.93; p < 0.01) The average absorbed doses to the salivary glands, lungs, kidneys, urinary bladder, and liver were found to be comparable with 99mTc-MDP bone scanning.
[CONCLUSION] The diagnostic performance of whole-body 99mTc-HYNIC PSMA-11 SPECT/CT is fairly comparable to 68Ga-PSMA PET/CT and offers a favorable dosimetry indicating its potential for PCa evaluation.
[ADVANCES IN KNOWLEDGE] 99mTc-PSMA-11 SPECT/CT may be an alternative and cost-effective tool for evaluation of initial PSMA disease burden as well as for response evaluation to PSMA targeted therapies.